I had previously mentioned SNMX. While researching a new lot of biotechs for potential purchase I ran across this company. I like biotech companies that have platforms for mutiple apps, DNDN casette for example. Here's one that is outside cancer to boot. [another big plus IMHO]
As I posted before Nature Biotechnology confirms SNMX IP moat as quite large in the area of flavor enhancers.
In essence they are using human taste receptors and high speed screen assays to find new products in comparison to limited taste throughput of human panels. Re: 200,000 at a whack versus IF&F human panels in the low 1000's.
Highly recommend listening to their last investors conference at: